SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

Zejula

GSK·GSK plc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA)
Time to market
Already on the market (approved 2017)
Why 3/10
Zejula is already FDA-approved and commercially marketed with no pending PDUFA date, pivotal readout, or regulatory binary in the next ~12 months. It is one product within GSK's massive diversified portfolio (~$100B market cap), so even a major label expansion or sales swing would not be a binary event for the stock. Per the rubric, an approved drug with no pending regulatory decision scores 3-5, and given the low concentration (small part of a large pipeline), a 3 is appropriate.
Actionable Insight NEUTRAL

Zejula is a mature, approved product within GSK's massive diversified portfolio, it is not a standalone binary catalyst. Investors should watch GSK's broader pipeline (vaccines, HIV, respiratory) and overall earnings rather than Zejula-specific news. The PARP inhibitor class faces increasing generic/biosimilar competition, so Zejula's revenue trajectory is likely to erode gradually rather than drive any single large stock move.

Price Chart

Loading chart...

Executive Summary

Zejula (niraparib) is an oral PARP inhibitor approved by the FDA since 2017 as maintenance therapy for ovarian cancer, developed and marketed by GSK plc. It competes in a crowded PARP inhibitor market alongside AstraZeneca/Merck's Lynparza (olaparib), Clovis Oncology's Rubraca (rucaparib), and Pfizer's Talzenna (talazoparib). Zejula is a mature, approved product within GSK's massive diversified pharmaceutical portfolio (~$100B market cap), it is not a binary catalyst for the stock. Recent supplemental FDA approvals (2025-2026) expanded labeling, and a companion diagnostic (MyChoice CDx) was approved in March 2026. However, Zai Lab's Greater China results show Zejula sales declining due to generic competition, and GSK's analyst consensus is a "hold" with a mean price target of $58.08, implying ~8.6% upside from the current ~$51.59.

How It Works

Zejula is a PARP inhibitor, it blocks an enzyme called PARP that cancer cells rely on to repair their damaged DNA. By preventing this repair, the drug causes cancer cells (especially those with BRCA or HRD mutations) to die, while leaving most healthy cells relatively unaffected. It is taken as a daily oral tablet.

Trial Status

Zejula was first FDA-approved in March 2017 for maintenance treatment of recurrent ovarian cancer. A landmark Phase 3 trial (PRIMA/NCT02655016) supported expansion to first-line maintenance in 2020. GSK completed a Phase 3 trial (NCT04475939, n=666) of niraparib + pembrolizumab in non-small cell lung cancer (completed March 2026). Multiple Phase 2 trials are completed or ongoing in prostate, endometrial, pancreatic, mesothelioma, and head & neck cancers, mostly investigator-sponsored. A Phase 2 trial combining niraparib with GSK4524101 in solid tumors is active but not recruiting.

The Two-Sided Case

▲ Bull Case4
Zejula remains a first-line maintenance option for ovarian cancer with a broad label covering all HRD-positive patients, supported by the PRIMA trial data.
GSK secured supplemental FDA approvals in 2025-2026 for labeling updates, keeping the product competitive.
Myriad Genetics received FDA approval for MyChoice CDx as the companion diagnostic for Zejula in March 2026, potentially expanding the addressable patient population by improving HRD testing access.
GSK's massive commercial infrastructure and diversified portfolio provide stable revenue streams that can weather competitive pressure on any single product.
▼ Bear Case5
Zejula faces intense competition from AstraZeneca/Merck's Lynparza (olaparib), which has a broader label and larger commercial footprint in the PARP inhibitor class.
Zai Lab reported declining Zejula sales in Greater China due to generic competition, signaling pricing pressure that may spread to other markets.
The PARP inhibitor class is maturing with multiple competitors, and Zejula has not demonstrated a clear efficacy or safety advantage over Lynparza.
GSK's analyst consensus is a 'hold' (recommendationMean 2.875) with 15 hold ratings vs. 14 buy/strong buy, reflecting limited near-term upside catalysts for the stock overall.
GSK's short-volume ratio has been elevated (35-41% range in mid-August 2026), and several large institutional holders trimmed or exited positions in Q2 2026.

Upcoming Catalysts

  • No scheduled PDUFA or pivotal readout for Zejula in the next ~12 months, it is an approved, marketed drug with no pending regulatory binary. Ongoing Phase 2 combination trials may yield data readouts but are not registrational.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 5

Hover a chip for the title
1 accessdata.fda.gov2 accessdata.fda.gov3 accessdata.fda.gov4 sec.gov5 accessdata.fda.gov